The bill aims to restrict the use of state funds for purchasing opioid overdose reversal drugs, specifically opioid antagonists, from entities involved in settlements related to the manufacture, sale, or distribution of prescription opioids. Effective after June 30, 2025, state funds or federal funding cannot be used to buy these medications from any person or their affiliates who have been part of such settlements. However, existing contracts for opioid antagonists that were established before July 1, 2025, will remain valid until their terms are fulfilled, but these contracts cannot be renewed after the specified date. Additionally, entities that have previously agreed to provide opioid antagonists as part of a settlement prior to September 1, 2024, are required to continue fulfilling their obligations until the settlement terms are completed.

The bill includes provisions for codification, indicating that the new regulations will be integrated into Title 18, chapter 1, part 1 of the state law. It also establishes that the act will take effect immediately upon passage and approval.